Polypeptide compositions with improved stability
The present invention provides means to improve the chemical stability of aqueous, parenteral pharmaceutical compositions comprising a polypeptide and glycerin. Reactive aldehydes are identified in commercial glycerins, and means for reducing such are provided. Convenient means are provided to assay for reactive aldehydes in glycerin, and a strong linear correlation between the level of reactive aldehydes in glycerin and chemical stability of compositions comprising a polypeptide and glycerin is demonstrated. The invention includes aqueous compositions comprising a polypeptide and glycerin having improved chemical stability compared to compositions previously known.
1. An aqueous, parenteral pharmaceutical composition for improving stability of a polypeptide comprising the polypeptide and glycerin, wherein the glycerin comprises propane-1,2,3-triol and reactive aldehyde impurities, the glycerin is derived from a non-animal source, the concentration of propane-1,2,3-triol is less than 500 mg/mL, and the content of reactive aldehyde impurities is less than 33 ppm.
2. The composition according to claim 1 , wherein the composition is a solution.
3. The composition according to claim 1 , wherein the composition is a suspension.
4. The composition according to claim 1 , wherein the glycerin concentration in the pharmaceutical composition is about 1 mg/mL to about 300 mg/mL.
5. The composition according to claim 4 , wherein the glycerin concentration is about 3 mg/mL to about 100 mg/mL.
6. The composition according to claim 5 , wherein the glycerin concentration is about 10 mg/mL to about 30 mg/mL.
7. The composition according to claim 6 , wherein the glycerin concentration is about 15 mg/mL to about 18 mg/mL.
8. The composition according to claim 1 , wherein the glycerin is derived from plants or propylene.
9. The composition according to claim 8 , wherein the glycerin is derived from propylene.
10. The composition according to claim 1 , wherein the glycerin has a reactive aldehyde content of less than 24 ppm.
11. The composition according to claim 10 , wherein the glycerin has a reactive aldehyde content of less than 15 ppm.
12. The composition according to claim 11 , wherein the glycerin has a reactive aldehyde content of less than 8 ppm.
13. The composition according to claim 12 , wherein the glycerin has a reactive aldehyde content of 3 ppm or lower.
14. The composition according to claim 1 , wherein the polypeptide is FSH, a FSH analog having deletion of one, two, three or more C-terminal residues of the FSH beta subunit, PTH, a PTH(1–38) fragment, a PTH(1–34) fragment, HGH, GLP-1 or an analog or derivative thereof, human insulin or an analog or derivative thereof, or a derivative of a human insulin analog.
15. The composition according to claim 14 , wherein the polypeptide is human insulin or an analog or derivative thereof, or a derivative of a human insulin analog.
16. The composition according to claim 15 , wherein the polypeptide is human insulin.
17. The composition according to claim 15 , wherein the polypeptide is an analog of human insulin.
18. The composition according to claim 17 , wherein the analog is Lys(B28)-Pro(B29)-human insulin.
19. The composition according to claim 17 , wherein the analog is Asp(B28)-human insulin.
20. The composition according to claim 17 , wherein the analog is Gly(A21)Arg(B31)Arg(B32)-human insulin.
21. The composition according to claim 15 , wherein the polypeptide is a derivative of human insulin or a derivative of a human insulin analog.
22. The composition according to claim 21 , wherein the derivative of a human insulin analog is myristoyl-ε-Lys(B29)-des(B30)-human insulin.
23. The composition according to claim 21 , wherein the derivative of human insulin is palmitoyl-ε-Lys(B29)-human insulin.